Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Stock Information for Oragenics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oragenics Inc.

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico
Oragenics Q3 2025 Shareholder Update
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
Oragenics Q2 2025 Shareholder Update
Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.